Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
Additional Business Intelligence Offerings
Clinical Diagnostics Insider
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Virtual Events & Webinars
Virtual events & webinars offer a variety of solutions and strategies for dealing with key issues labs face.
Lab Industry Advisor Subscriptions Include
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
CMS Slated to Close Change Healthcare Payment Program
Program meant to ease cash flow disruptions experienced by some Medicare providers and suppliers due to the cyberattack will conclude in mid-July
Personal Genome Diagnostics, VA Partner for Precision Oncology Program
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Personal Genome Diagnostics' CancerSelect targeted gene profiling panel has been selected for use in all newly-diagnosed lung cancer patients in the U.S. Department of Veterans Affairs (VA) New...
Metabolomic Markers Improve Cardiovascular Risk Prediction
...
Register
Sequencing Rapidly Emerging for Epidemiology, Outbreak Control
...
Register
Evidence Needed for Cost-Effectiveness of Sequencing
...
Register
High-Res Sequencing Data Differentiates Outbreak Clusters
...
Register
At Lab Revolution Conference, a Peek Inside Quest’s ‘Lab of the Future’
By Stephanie Murg, Managing Director, G2 Intelligence What does the lab of the future look like? This question was addressed by a broad range of experts at G2 Intelligence’s Lab Revolution 2015 conference, held March 11-13 in Orlando, Florida. Among the speakers...
Coverage for Electron Microscopy Left to MACs
By Christopher P. Young, Editor, G2 Compliance Advisor The Centers for Medicare and Medicaid Services (CMS) has removed the national coverage determination (NCD) for electron microscopy (EM) from the Medicare National Coverage Determinations Internet only manual...
FDA, AACR and ASCO Seeking to Harmonize Companion Diagnostics for Cancer Treatments
By Kelly A. Briganti, Editorial Director, G2 Intelligence Concerned that cancer patients may not receive "optimal care" when there are "multiple targeted therapy-companion diagnostic pairs," the U.S. Food and Drug Administration (FDA), American Association for...
Quest Strikes Deal With Personalis on Pediatric Exome Testing
By Ron Shinkman, Editor, Laboratory Industry Report Quest Diagnostics has teamed with the California-based testing firm Personalis to provide a whole exome sequencing product to detect rare genetic disorders among pediatric patients. The product, known as Neurome,...
Online Marketing of Personalized Oncology Services May Be Misleading
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Online marketing of personalized cancer tests and services frequently overemphasize their reported benefits, neglect to disclose their limitations, and promote genetic tests that do not have...